BTG (LON:BTG)‘s stock had its “neutral” rating reaffirmed by research analysts at JPMorgan Chase & Co. in a report released on Monday, January 15th.
Several other equities analysts have also issued reports on the company. Deutsche Bank reaffirmed a “buy” rating and issued a GBX 775 ($10.87) target price on shares of BTG in a report on Friday, October 6th. Numis Securities reissued a “buy” rating and set a GBX 900 ($12.62) price objective on shares of BTG in a report on Friday, December 8th. Finally, Peel Hunt reissued a “hold” rating and set a GBX 680 ($9.53) price objective on shares of BTG in a report on Tuesday, November 14th. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of GBX 774.13 ($10.85).
Shares of BTG (LON BTG) traded down GBX 46.50 ($0.65) during trading on Monday, hitting GBX 670.50 ($9.40). The stock had a trading volume of 1,167,248 shares, compared to its average volume of 538,223. The stock has a market capitalization of $2,600.00 and a P/E ratio of 3,528.95. BTG has a 12-month low of GBX 535 ($7.50) and a 12-month high of GBX 784 ($10.99).
BTG (LON:BTG) last released its earnings results on Tuesday, November 14th. The company reported GBX 21 ($0.29) earnings per share (EPS) for the quarter, meeting the consensus estimate of GBX 21 ($0.29). The company had revenue of £341.30 million during the quarter. BTG had a return on equity of 10.80% and a net margin of 15.50%.
COPYRIGHT VIOLATION WARNING: “BTG (BTG) Rating Reiterated by JPMorgan Chase & Co.” was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international copyright legislation. The legal version of this piece can be accessed at https://www.dispatchtribunal.com/2018/02/06/btg-btg-stock-rating-reaffirmed-by-jpmorgan-chase-co.html.
BTG Company Profile
BTG plc is engaged in the business of healthcare, focusing on Interventional Medicine therapies for liver cancer, emphysema and vascular disorders, specialty pharmaceuticals for acute care uses, and a licensing business. The Company operates through three segments: Interventional Medicine, Specialty Pharmaceuticals and Licensing.
Receive News & Ratings for BTG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BTG and related companies with MarketBeat.com's FREE daily email newsletter.